Glaxo Soliciting Regulatory Approval of COPD Drug
Submitted by Dinesh Chandra Gaur on Mon, 01/09/2012 - 13:57
GlaxoSmithKline has announced that they would be applying their chronic Obstructive Pulmonary Disease (COPD) drug "Relovair" for regulatory approval by the mid of 2012. They are expecting to launch the medicine in Europe as well, but for the purpose of asthma.
Anglo-American drugs giant GlaxoSmithKline said clinical trial has given them an assurance that their drug would be a great hit in the multibillion-dollar market of lung medicines.
Precedent Seen in Ruling against Drug Company
Submitted by Pallavi Sharma on Tue, 10/04/2011 - 10:52
According to latest reports, it has been claimed that a pharmacist has got an edge over GlaxoSmithKline to win an imperative lawsuit filed by him against the drug maker.
On the other hand, the Pharmacy Guild has claimed it as crucial precedent, which associated a national remind of Marevan (warfarin) in 2010.
GlaxoSmithKline to Pay Losses to Otara Chemist
Submitted by Pallavi Sharma on Mon, 10/03/2011 - 11:54
It has been revealed according to a recent report that GlaxoSmithKline, the drug firm, has been ordered to pay sums incurred by Ian Johnson Pharmacy for the losses it had to incur due to faulty medicine stocks.
It was the incident when the Marevan brand of medicine for blood thinning had to be called back by the regulatory due to impurity in them. The drug firm had to pay for the losses incurred by the pharmacy.
Efficient Drug Pricing Need of Hour
Submitted by Dinesh Chandra Gaur on Sat, 09/24/2011 - 10:35
It has been recently revealed by Andrew Witty the CEO of GlaxoSmithKline, the drug giant, that the world is currently in need for effective pricing of drugs. It is essential that everyone has the access to drugs, as and when they need them, in order to foster homogeneity and eradicate diseases from the world. With the increasing concerns of the world government about belt-tightening, it is essential that drug prices are manipulated for the benefit of people.
GSK Launches Probe into Augmentin
Submitted by Pallavi Sharma on Mon, 06/20/2011 - 11:57
The drug maker, GSK has launched a probe into Augmentin antibiotic after the drug was banned by a Chinese drug authority, State Food and Drug Administration (SFDA). The drug is commonly prescribed to children and is a major contributor to the annual sales of GSK.
GSK to Acquire 51% Stake in GSKNB
Submitted by Dinesh Chandra Gaur on Wed, 06/15/2011 - 10:52
On Tuesday, the British drug maker GlaxoSmithKline (GSK) announced that soon it will be buying 51% interest of Shenzhen Neptunus in the joint venture company. It has been revealed that after acquiring its Chinese partner GSK will become the sole owner of GSKNB.
